Science & Insights / Retatrutide
Retatrutide and Blood Tests
One person’s results after nine months of use
Looking healthier and being healthier do not always mean the same thing. Weight loss, improved fitness and a leaner physique can be meaningful changes, but they cannot reveal everything happening inside the body.
That distinction matters when discussing peptides. The term covers a wide range of compounds with very different functions and levels of evidence. Results involving one compound cannot establish the safety or effectiveness of another.
At Everform Pharma, we believe peptide education should make those differences clear. This article examines one person’s reported blood-test changes during approximately nine months of retatrutide use, alongside substantial weight loss and use of other peptides. The results offer observations to consider, rather than proof of cause or safety.
Nine months while taking retatrutide
In the supplied account, a 41-year-old man describes losing 35 pounds—approximately 16 kilograms—in four months after starting retatrutide, alongside experimenting with several other peptides. He compared baseline blood tests with a second set taken approximately nine months later.
He reported feeling fitter and seeing substantial physical improvements. His central question, however, was whether those visible changes might conceal less obvious problems.
The figures below are his reported results. Everform Pharma has not independently verified the laboratory reports, testing conditions or substances used. The transcript does not consistently provide units, laboratory reference ranges or a complete compound history, which limits interpretation.
Cardiovascular markers: encouraging changes with important limits
Some of the largest reported changes involved cholesterol and triglycerides.
| Marker | Baseline | Nine months later |
|---|---|---|
| Total cholesterol | 182 | 166 |
| LDL cholesterol | 108 | 87 |
| HDL cholesterol | 52 | 63 |
| Triglycerides | 112 | 74 |
| Blood pressure | 129/84 | 111/72 |
Units for the lipid results were not explicitly supplied. Blood pressure is reported in the conventional mmHg format.
The lipid results moved in generally favourable directions. However, the blood-pressure readings were taken on separate occasions, with the later measurement reportedly recorded at a dental appointment. They do not establish a sustained change on their own.
Published phase 2 research on retatrutide has also reported improvements in several cardiometabolic measures, including blood pressure and selected lipid measures. The same trial identified dose-related increases in heart rate, illustrating why favourable changes in some markers must be considered alongside adverse effects.[1]
In this personal account, weight loss, diet, exercise and multiple compounds changed together. There is no reliable way to assign the results to one peptide or separate a direct drug effect from the effects of losing weight. Improved risk markers also do not, by themselves, prove fewer heart attacks or strokes.
Kidney and liver results: useful information, not an all-clear
The individual reported relatively stable creatinine and estimated glomerular filtration rate, or eGFR, although the transcript did not provide their values. Blood urea nitrogen, or BUN, increased from 17 to 24.
BUN is influenced by several factors. Higher protein intake and dehydration can raise it, but these explanations should not be assumed without considering the wider clinical picture.[2] The transcript alone cannot establish why this result changed.
Kidney assessment may also involve urine testing. The US National Institute of Diabetes and Digestive and Kidney Diseases describes both eGFR and urine albumin testing as important tools for identifying kidney disease.[3] Stable blood markers alone therefore provide an incomplete assessment.
The reported liver enzyme changes were modest: AST increased from 19 to 21, while ALT rose from 19 to 26. The speaker described both as remaining within his laboratory's reference ranges, with no concerning findings elsewhere in his liver panel.
That is reassuring within the limits of the account. It does not demonstrate that every substance used was harmless, exclude all liver disease or establish long-term safety.
Blood glucose: little movement is still a finding
HbA1c changed from 5.4% to 5.3%, while fasting glucose rose from 91 to 95, with glucose units unspecified in the transcript.
The speaker had expected a larger improvement after losing weight. However, these two comparisons do not establish whether insulin sensitivity improved, worsened or remained unchanged. They also do not support a claim that the peptide combination caused metabolic harm.
The broader lesson is to resist treating every small numerical movement as a meaningful biological change. Results need to be interpreted alongside testing conditions, symptoms and repeat measurements where appropriate.
Thyroid testing: understand what was measured
TSH was almost unchanged, moving from 1.90 to 1.89. The account presented this as reassuring after substantial weight loss and periods of reduced food intake.
TSH is an important initial test of thyroid function. Depending on the clinical circumstances, free T4 and other investigations may be needed to interpret thyroid health more fully.[4]
A stable TSH result should not be stretched into evidence that all thyroid-related risks have been excluded. It answers a narrower question about the marker measured at those two points in time.
Inflammation: a low result does not identify the cause
High-sensitivity C-reactive protein, or hs-CRP, reportedly fell from 0.3 to below 0.2, the laboratory's stated reporting threshold. Units were not supplied.
The individual linked his interest in this marker to feeling better physically and experiencing less back pain. Yet the results cannot establish that a peptide reduced inflammation or repaired an injury.
Because the follow-up result was below a reporting threshold, its exact value is unknown. The account also lacks a comparison group and involved several simultaneous changes. The finding is an observation worth recording, rather than evidence for a specific mechanism or treatment claim.
Testosterone and symptoms: the numbers are only part of the picture
The speaker reported reduced libido despite relatively small changes in the hormone results he shared.
| Marker | Baseline | Nine months later |
|---|---|---|
| Total testosterone | 627 | 589 |
| Free testosterone | 74.5 | 72.9 |
| Bioavailable testosterone | 153.3 | 146.8 |
| SHBG | 40 | 38 |
Units, assay methods and reference ranges were not supplied.
These comparisons cannot establish a clinically significant hormone decline or identify the cause of his symptoms. They also cannot show that the compounds preserved testosterone during weight loss.
The practical lesson is that symptoms deserve attention even when the numbers appear broadly similar. A laboratory result is one part of an assessment, rather than a substitute for it.
What this account contributes to the discussion
The strongest feature of this account is the existence of a baseline. Without earlier measurements, it would be much harder to describe what changed.
Its greatest limitation is attribution. Multiple compounds, considerable weight loss and lifestyle changes occurred together, while the full laboratory reports and exposure history were unavailable. Nine months of observations from one person cannot establish the safety of a compound, a combination or future use.
Our view at Everform Pharma is that personal reports can generate useful questions, but they should remain clearly separate from controlled research. Encouraging blood results are valuable observations. They are not a safety certificate for everything taken along the way.
Understanding peptides means looking beyond visible results: examining the evidence for each compound, recognising what a test actually measures and being honest about what remains unknown.
This article discusses an individual account for educational purposes. It does not recommend self-experimentation or provide a testing or treatment protocol. Personal symptoms and laboratory results should be reviewed with a qualified healthcare professional.
References
[1] Jastreboff AM et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity—A Phase 2 Trial. New England Journal of Medicine (2023). Read source ↗
[2] MedlinePlus. BUN (Blood Urea Nitrogen). Read source ↗
[3] NIDDK. Chronic Kidney Disease Tests & Diagnosis. Read source ↗
[4] American Thyroid Association. Thyroid Function Tests. Read source ↗
